表紙
市場調査レポート

持続的血糖モニタリングシステムの世界市場:国別 (米国・カナダ・インド・中国・日本・英国) 市場、企業プロファイル、シェア、動向、分析、規模、機会、分類と2015年〜2021年の予測

Global Continuous Glucose Monitoring System Market by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Size, Opportunities, Segmentation and Forecast 2015 - 2021

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 345618
出版日 ページ情報 英文 122 Pages
納期: お問合せ
価格
こちらの商品の販売は終了いたしました。
Back to Top
持続的血糖モニタリングシステムの世界市場:国別 (米国・カナダ・インド・中国・日本・英国) 市場、企業プロファイル、シェア、動向、分析、規模、機会、分類と2015年〜2021年の予測 Global Continuous Glucose Monitoring System Market by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Size, Opportunities, Segmentation and Forecast 2015 - 2021
出版日: 2015年08月02日 ページ情報: 英文 122 Pages

当商品の販売は、2016年05月07日を持ちまして終了しました。

概要

糖尿病患者の血糖モニタリングにおいて、持続的血糖モニタリングシステムの登場は画期的なものとなっています。MEdtronicとDexcomが主な参入企業ですが、このほか一部の地域においてAbbottが参入しています。持続的血糖モニタリングシステムは高い法規制の壁があり、承認されるまでに厳しいテストをくぐり抜けなければなりません。より安価で使いやすく、FDAの承認プロセスも受けやすい自己モニタリング装置 (SMBG) と競合しています。各社はよりミスの少ない新規のシステムを導入しています。

当レポートでは、世界の持続的血糖モニタリングシステム市場について調査し、市場の動向と2021年までの収益予測と成長率、業界分析、競合動向、地域別動向、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 市場概要

  • 持続的血糖モニタリングシステムとは
  • サプライヤー、製造業者、エンドユーザーの役割に関するバリューチェーン分析
  • 主な購買基準

第3章 市場の決定因子

  • 市場のモチベーター
  • 阻害因子
  • 機会
  • 課題

第4章 セクター分析:糖尿病ケア

第5章 装置別市場

  • 長期継続センサー
  • トランスミッターおよびレシーバー
  • インスリンポンプ

第6章 用途別

第7章 競合インテリジェンス

第8章 市場シェア分析

  • 主要企業分析
    • Dexcom
    • MEdtronic
    • Abbott Diabetic Care
    • 市場シェア
    • 結論

第9章 地域別分析

  • 北米
  • カナダ
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ

第10章 企業プロファイル:ベンチマークスタディ

  • Medtronic Inc.
  • Dexcom
  • Abbott
  • Johnson and Johnson (J&J) (Animas Corp)
  • Insulet Corp
  • Tandem Diabetes
  • Echo Therapeutics

図表

目次
Product Code: HME-340714

Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for paediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers.

Companies profiled include

  • 1. Medtronic Inc.
  • 2. Dexcom
  • 3. Abbott
  • 4. Johnson And Johnson (Animas Corp)
  • 5. Insulet Corp
  • 6. Tandem Diabetes
  • 7. Echo Therapeutics

This Occams Research Report covers

  • 1. Historical data
  • 2. Revenue forecasts, growth rates and CAGR upto 2021
  • 3. Industry Analysis
  • 4. Competitive Analysis
  • 5. Key geographic growth data
  • 6. Deep profiles top competitive companies

Table of Contents

Chap 1. Executive Summary

Chap 2. Market Overview

  • 2.1. What ARE CGMS?
  • 2.2. Value Chain Analysis of the role of suppler, manufacturer, and end user in the CGMS market
    • 2.2.1. Suppliers enabling financially weak players
    • 2.2.2. Manufacturers facing regulations and operational cost issues
    • 2.2.3. Pediatrics and hospitals will lead the future market growth
  • 2.3. Key Buying Criteria
    • 2.3.1. Convenience factor
    • 2.3.2. Price is the key concern
    • 2.3.3. Improved Accuracy leads to easier regulation norms
    • 2.3.4. Collaboration of the two main manufacturers
    • 2.3.5. Development of durable sensors
    • 2.3.6. Development of APD
    • 2.3.7. Focus on developing Asian markets
    • 2.3.8. Partnerships and Collaborations - the winning strategies
    • 2.3.9. Innovation Important for new entrants

Chap 3. Market Determinants

  • 3.1. CGMS Market Motivators
    • 3.1.1. Diabetes population rise leads to larger market opportunity
    • 3.1.2. Rise in the global health expenditure and emerging Asian Market
    • 3.1.3. Increased R&D funding for faster approvals and development of APD
    • 3.1.4. Insulin Pump manufacturers willing to integrate CGMS and insulin pump technology
    • 3.1.5. Private Insurers INCREASING CGMS AFFORDABILITY
    • 3.1.6. New technology can bring down prices
  • 3.2. RESTRAINTS
    • 3.2.1. Government Regulations delaying the processes
    • 3.2.2. Established SMBG DEVICE manufacturers restraining CGMS growth
    • 3.2.3. Poor access to the healthcare services in developing markets
  • 3.3. Opportunities
    • 3.3.1. Growing diabetic population
    • 3.3.2. Emergence of new segment - Pediatrics
    • 3.3.3. Case study on pediatrics use
    • 3.3.4. Development of artificial pancreas
  • 3.4. Challenges in CGMS market
    • 3.4.1. High Price
    • 3.4.2. Unmet Diabetic needs
    • 3.4.3. No government aid makes it difficult for the consumer

Chap 4. Sector Analysis: Diabetes Care

Chap 5. CGMS Market By devices

  • 5.1. Long lasting Sensors: the need of the hour
    • 5.1.1. Factors influencing CGM sensor development
  • 5.2. Transmitters and receivers - The standalone system
    • 5.2.1. Price the major restraint for transmitters and receivers
  • 5.3. Insulin Pumps hold the future
    • 5.3.1. Innovation and Collaboration the mainstay for insulin pumps

Chap 6. By Application

  • 6.1. Professional CGMS (used by healthcare professionals)
    • 6.1.1. Professional CGMS types
    • 6.1.2. Case study on use of CGMS in hospital settings
    • 6.1.3. Case study 2:Medtronic Real Time CGMS in rural Settings
    • 6.1.4. Personal CGMS segmented on the basis of Age groups

Chap 7. Competitive Intelligence

  • 7.1. Key Strategies to help CGMS market drive acceptance
    • 7.1.1. Innovation The Key Industry to Overcome Competition
    • 7.1.2. Technology Leveraging - Key focus of partnerships Among industry players
      • 7.1.2.1. Key objective of partnerships and agreements in the CGMS market
      • 7.1.2.2. Major agreements signed by CGMS manufacturers since 2007
    • 7.1.3. Product Launch - a make or break marketing strategy
      • 7.1.3.1. Recent product launches
    • 7.1.4. Acquisitions Still Remain Niche in the CGMS Market

Chap 8. Market Share Analysis

  • 8.1. Key Company Analysis
    • 8.1.1. Dexcom
    • 8.1.2. Medtronic
    • 8.1.3. Abbott Diabetic Care
    • 8.1.4. Market Share
    • 8.1.5. Conclusion

Chap 9. Geographical Analysis

  • 9.1. North America
    • 9.1.1. United States of America
      • 9.1.1.1. A developed economy a Major business driver
      • 9.1.1.2. Awareness is the key to CGMS adoption
      • 9.1.1.3. Medicare and reimbursements are the future drivers
      • 9.1.1.4. High number of T1D
      • 9.1.1.5. Regulations Obstructing market expansion
        • 9.1.1.5.1. US FDA guidelines for the development of artificial pancreas
          • 9.1.1.5.1.1. Primary components of an APD
          • 9.1.1.5.1.2. Secondary component
      • 9.1.1.6. Key Market Players in the US
  • 9.2. Canada
    • 9.2.1. Regulations in Canada
  • 9.3. Europe
    • 9.3.1. European Union (EU)
      • 9.3.1.1. THE UK 87
        • 9.3.1.1.1. Regulations in the UK
        • 9.3.1.1.2. Key companies in the UK
      • 9.3.1.2. France
      • 9.3.1.3. Germany
      • 9.3.1.4. CGMS business in the EU
  • 9.4. Asia Pacific
    • 9.4.1. China
      • 9.4.1.1. Regulations in China
    • 9.4.2. India
      • 9.4.2.1. Regulation in India
      • 9.4.2.2. CGMS in India
    • 9.4.3. Australia
      • 9.4.3.1.1. Regulations in Australia
  • 9.5. Latin America
    • 9.5.1. Factsheet of diabetes statistics in Latin America
      • 9.5.1.1. Brazil
      • 9.5.1.2. Argentina
      • 9.5.1.3. Mexico
    • 9.5.2. Rest of the World
      • 9.5.2.1. Middle-East and North Africa
      • 9.5.2.2. Africa

Chap 10. Corporate Profile: Benchmark Study

  • 10.1. Medtronic Inc.
    • 10.1.1. Business Profile
    • 10.1.2. Product Portfolio
    • 10.1.3. Revenue Analysis
    • 10.1.4. Strategic Inputs
  • 10.2. Dexcom
    • 10.2.1. Location
    • 10.2.2. Business Profile
    • 10.2.3. Product Portfolio
    • 10.2.4. Revenue Analysis
    • 10.2.5. Strategic inputs
  • 10.3. Abbott
    • 10.3.1. Locations
    • 10.3.2. Business Profile
    • 10.3.3. Product Portfolio
    • 10.3.4. Revenue Analysis
    • 10.3.5. Strategic inputs
  • 10.4. Johnson and Johnson (J&J) (Animas Corp)
    • 10.4.1. Locations
    • 10.4.2. Business Portfolio
    • 10.4.3. Product Portfolio
    • 10.4.4. Revenue Analysis
  • 10.5. Insulet Corp
    • 10.5.1. Geography
    • 10.5.2. Business Portfolio
    • 10.5.3. Product Portfolio
    • 10.5.4. Revenue Analysis
    • 10.5.5. Strategic inputs
  • 10.6. Tandem Diabetes
    • 10.6.1. Business Portfolio
    • 10.6.2. Revenue Analysis
  • 10.7. Echo Therapeutics
    • 10.7.1. Business Portfolio
    • 10.7.2. Product Portfolio
    • 10.7.3. Revenue Analysis

Table List

  • TABLE 1: Summary table: Global CGMS market, 2013-2021 (USDmillion)
  • TABLE 2: Comparison of price of SMBG and CGM (US)
  • TABLE 3: Comparative prices of sensors and test strips (based on various online retail prices)
  • TABLE 4: Ratio (Physician per 1,000 people)
  • TABLE 5: Comparison of price (US)
  • TABLE 6: CGM market by device (2013-20)
  • TABLE 7: Cost Of sensors (in USD)
  • TABLE 8: Cost of Transmitters and Receivers (in USD)
  • TABLE 9: Cost of insulin pumps (in USD)
  • TABLE 10: CGM market by application (2013-2021)
  • TABLE 11: Global CGMS by age market (2013-2021), in USD million
  • TABLE 12: Devices approved for pediatric use
  • TABLE 13: Revenue by Geography (2013-2021)
  • TABLE 14: Diabetes Statistics
  • TABLE 15: French Diabetic Statistics
  • TABLE 16: Germany Diabetic Statistics
  • TABLE 17: China Diabetes Statistics
  • TABLE 18: Statistics for diabetes in India
  • TABLE 19: Statistics for diabetes Australia
  • TABLE 20: Life expectancy in Latin America
  • TABLE 21: Total revenue (Geography; 2013)
  • TABLE 22: Revenue (Segment wise; 2013)
  • TABLE 23: Revenue (Segment wise; 2013)

Figures List

  • FIGURE 1: Key Buying Criteria 2013 versus 2021
  • FIGURE 2: 2013 GDP of top 10 Asian Countries (USD billion)
  • FIGURE 3: Diabetic Population, 2013 (in millions)
  • FIGURE 4: Per Capita income comparison (in USD)
  • FIGURE 5: SmartPhone technology
  • FIGURE 6: Process of obtaining a market approval through FDA
  • FIGURE 7: global Sensor market revenue (2013-2021) (USD million)
  • FIGURE 8: global Transmitters and receivers market (2013-2021), in USD million
  • FIGURE 9: global Insulin Pumps market (2013-2021), in USD million
  • FIGURE 10: Global CGMS for Diagnostics and Clinics (2013-2021), in USD million
  • FIGURE 11: Global CGMS for Hospitals (2013-2021), in USD million
  • FIGURE 12: Global CGMS in Home settings (2013-2021), in USD million
  • FIGURE 13: Global CGM for pediatric market (2013-2021), USD million
  • FIGURE 14: Intra relationship of strategies
  • FIGURE 15: Medtronic's Product development timeline
  • FIGURE 16: Dexcom Inc Revenue (In million USD)
  • FIGURE 17: Medtronic Diabetes -Revenue (In million USD)
  • FIGURE 18: Market Share
  • FIGURE 19: Percentage share (geography)
  • FIGURE 20: North America, 2013-2021, in USD million
  • FIGURE 21: The US (2013-2021), in USD million
  • FIGURE 22: Age standardized prevalence of Diabetes in Aboriginals and Non Aboriginals
  • FIGURE 23: Canada. 2013-2021, in USD million
  • FIGURE 24: Europe, 2013-2021
  • FIGURE 25: Data on diabetic population in Europe
  • FIGURE 26: THE UK, 2013-2021
  • FIGURE 27: France, 2013-2021
  • FIGURE 28: Germany, 2013-2021
  • FIGURE 29: Asia Pacific, 2013-2021
  • FIGURE 30: China, 2013-2021
  • FIGURE 31: India (2013-2021)
  • FIGURE 32: Australia (2013-2021)
  • FIGURE 33: Process of supplying a medical device in Australia for an overseas manufacturer
  • FIGURE 34: Latin American market, 2013-2021(USD million)
  • FIGURE 35: Life expectancy graph
  • FIGURE 36: Rest of the world (2013-2021)
  • FIGURE 37: Total revenue (Product mix; 2013)
  • FIGURE 38: Powerzone Mapping (Medtronic vs. Dexcom)
Back to Top